内視鏡的スリーブ胃形成術(ESG)肥満症前向き試験(EGO-Trial)
内視鏡的スリーブ胃形成術(ESG)の肥満に対する前向き試験
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.
While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.
Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.
Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.
To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.
This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Armelle TAKEDA
- 電話番号:0033 390 413608
- メール:armelle.takeda@ihu-strasbourg.eu
研究連絡先のバックアップ
- 名前:Clinical Research Team
- メール:rc-ihu@ihu-strasbourg.eu
研究場所
-
-
-
Baie-Mahault、グアドループ
- まだ募集していません
- Clinique les Eaux Claires
-
コンタクト:
- Venetia AVENDANO
- 電話番号:0033 5 90 25 95 65
- メール:zulemacu@yahoo.com
-
-
-
-
-
Aix-en-Provence、フランス
- 募集
- Hôpital Privé de Provence
-
コンタクト:
- Hugues SEBBAG
- 電話番号:0033 4 42 21 12 11
- メール:hsebbag.ppr@hotmail.fr
-
Besançon、フランス
- まだ募集していません
- Polyclinique de Franche-Comté
-
コンタクト:
- Henry-Alexis MERCOLI
- 電話番号:0033 3 81 41 81 41
- メール:docteur.mercoli@gmail.com
-
Lille、フランス
- まだ募集していません
- Hôpital HURIEZ
-
コンタクト:
- Robert CAIAZZO
- 電話番号:0033 3 20 44 42 73
- メール:robert.caiazzo@univ-lille2.fr
-
Lyon、フランス
- 募集
- Clinique de la Sauvegarde
-
コンタクト:
- Marie-Cécile BLANCHET
- 電話番号:+33 4 37 49 70 10
- メール:blanchet@chirurgien-digestif.com
-
Lyon、フランス
- 募集
- Hospices Civils de Lyon - Hôpital Edourard HERRIOT
-
コンタクト:
- Maud ROBERT
- 電話番号:0033 4 72 11 62 61
- メール:Maud.robert@chu-lyon.fr
-
Montpellier、フランス
- まだ募集していません
- Clinique Clémentville
-
コンタクト:
- Marta SILVESTRI
- 電話番号:0033 4 67 06 70 00
- メール:docteur.m.silvestri@gmail.com
-
Saint-Etienne、フランス
- まだ募集していません
- Centre Mutualiste de l'Obésité
-
コンタクト:
- Pierre BLANC
- 電話番号:0033 4 77 81 82 88
- メール:PBLANC@mutualite-loire.com
-
Saint-Grégoire、フランス
- まだ募集していません
- CHP Saint-Grégoire
-
コンタクト:
- Adrien STERKERS
- 電話番号:+33 2 99 23 93 10
- メール:asterkers@vivalto-sante.com
-
Strasbourg、フランス
- 募集
- Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
-
コンタクト:
- Silvana PERRETTA
- 電話番号:0033 3 69 55 05 31
- メール:perretta@unistra.fr
-
Sète、フランス
- 募集
- Polyclinique Sainte Thérèse
-
コンタクト:
- Thibaut COSTE
- 電話番号:0033 4 67 18 88 20
- メール:thibautcoste@gmail.com
-
Échirolles、フランス
- まだ募集していません
- Clnique des Cèdres
-
コンタクト:
- Fabien STENARD
- 電話番号:0033 4 56 58 14 90
- メール:fabien.stenard@cliniquedescedres.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult patients with obesity scheduled for endoscopic gastroplasty
説明
Inclusion Criteria:
- Patients aged 18 to 75 years.
- Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
- Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
- Patients not eligible for bariatric surgery or does not wish to undergo it.
- Patients who can undergo general anesthesia.
- Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
- Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
- Patients affiliated with the French social security system.
Exclusion Criteria:
- Patients with contraindications to endoscopic gastroplasty
- Patients with active peptic ulcer disease or significant gastroparesis
- Patients with a history of bariatric, gastric, or esophageal surgery.
- Patients who have started medication in the last 3 months that is known to cause weight gain.
- Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
- Patients with unstable and precarious health, as determined and assessed by the investigator.
- Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
- Patients who are currently excluded (as determined by a previous or ongoing study).
- Patients under judicial protection.
- Patients under guardianship, conservatorship or subject to any form of protective supervision
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
内視鏡的胃形成術(ESG)を予定しているすべての成人肥満患者
|
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total Body Weight Loss
時間枠:At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery |
At the inclusion and 24 months after procedure
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Excess weight loss
時間枠:At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure |
At the inclusion and 24 months after procedure
|
|
Body Mass Index (BMI)
時間枠:From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Adverse events
時間枠:From ESG procedure to the end of participation at 24 months post-procedure
|
Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Comorbidities improvement
時間枠:From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Quality of life improvement
時間枠:From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Additional treatments
時間枠:From ESG procedure to the end of participation at 24 months post-procedure
|
Compilation of additional treatments or revisions required after the procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Silvana PERRETTA, MD-PhD、Hôpitaux Universitaires de Strasbourg
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 25-004
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。